Patents by Inventor Elias Quijano
Elias Quijano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11872286Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.Type: GrantFiled: August 30, 2022Date of Patent: January 16, 2024Assignee: Yale UniversityInventors: Elias Quijano, Peter Glazer
-
Patent number: 11850284Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.Type: GrantFiled: August 30, 2022Date of Patent: December 26, 2023Assignee: Yale UniversityInventors: Elias Quijano, Peter Glazer
-
Publication number: 20230303719Abstract: The disclosure provides humanized 3E10 antibodies and antigen binding fragments thereof. Compositions and methods of using the humanized 3E10 antibodies and antigen binding fragments thereof to deliver cargo are also disclosed.Type: ApplicationFiled: March 2, 2023Publication date: September 28, 2023Inventors: Elias Quijano, Peter Glazer, Stephen Squinto, Dale Ludwig
-
Patent number: 11766400Abstract: Biodegradable contraceptive implants and methods of making and using thereof, are preferably formed of poly(?-pentadecalactone-co-p-dioxanone) [poly(PDL-co-DO)], a family of polyester copolymers that degrade slowly in the presence of water. The material is suitable as the basis of a biodegradable contraceptive implant that provides sustained release of a progestin at a rate similar to a commercially available nondegradable implant. In a preferred embodiment, the progestin is levonorgestrel (LNG), a hormone that prevents pregnancy by preventing the release of an egg from the ovary or by preventing fertilization of the egg by sperm. The implant may be inserted subcutaneously, allowing degradation over a period of up to about 18 or 24 months, eliminating the need for removal by a trained practitioner.Type: GrantFiled: October 24, 2017Date of Patent: September 26, 2023Assignees: YALE UNIVERSITY, FAMILY HEALTH INTERNATIONALInventors: W. Mark Saltzman, Elias Quijano, Fan Yang, Zhaozhong Jiang, Derek Owen
-
Publication number: 20230277658Abstract: Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.Type: ApplicationFiled: November 9, 2022Publication date: September 7, 2023Applicant: Yale UniversityInventors: Elias QUIJANO, Adele RICCIARDI, Raman BAHAL, Audrey TURCHICK, Nicholas ECONOMOS, W. Mark SALTZMAN, Peter GLAZER
-
Publication number: 20230272115Abstract: Compositions for enhanced gene editing and methods of use thereof are. The composition contains a cell-penetrating antibody and a donor oligonucleotide containing a sequence that can correct a mutation in a cell's genome. Preferably, the composition does not contain a nuclease, PNA, or nanoparticle. The compositions are used to modify the genome of a cell by contacting the cell with an effective amount of the composition. Genomic modification occurs at a higher frequency both ex vivo and in vivo, when cells are contacted with the cell-penetrating antibody and donor oligonucleotide as compared to the absence of the cell-penetrating antibody.Type: ApplicationFiled: November 9, 2022Publication date: August 31, 2023Applicant: Yale UniversityInventors: Elias QUIJANO, Audrey TURCHICK, Peter GLAZER
-
Publication number: 20230265214Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.Type: ApplicationFiled: August 31, 2021Publication date: August 24, 2023Inventors: Elias Quijano, Peter Glazer, Bruce C. Turner, Audrey Turchick, W. Mark Saltzman
-
Publication number: 20230227583Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.Type: ApplicationFiled: August 31, 2020Publication date: July 20, 2023Applicant: Yale UniversityInventors: Elias QUIJANO, Peter GLAZER
-
Publication number: 20230093888Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.Type: ApplicationFiled: August 30, 2022Publication date: March 30, 2023Applicant: Yale UniversityInventors: Elias QUIJANO, Peter GLAZER
-
Publication number: 20230093460Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.Type: ApplicationFiled: August 30, 2022Publication date: March 23, 2023Applicant: Yale UniversityInventors: Elias QUIJANO, Peter GLAZER
-
Publication number: 20230085308Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.Type: ApplicationFiled: August 30, 2022Publication date: March 16, 2023Applicant: Yale UniversityInventors: Elias QUIJANO, Peter GLAZER
-
Publication number: 20230032060Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.Type: ApplicationFiled: August 30, 2022Publication date: February 2, 2023Applicant: Yale UniversityInventors: Elias QUIJANO, Peter GLAZER
-
Publication number: 20220372474Abstract: Peptide nucleic acid (PNA) oligomers having one or more hydroxymethyl ?-substitutions, also referred to herein as “ser?PNA”, are provided. The hydroxymethyl ?-substitution preserves and amplifies the helical preorganization that is valuable for DNA duplex invasion by the oligomer. ser?PNA-containing triplex-forming molecules can be used in combination with a donor DNA fragment to facilitate genome modification in vitro and in vivo.Type: ApplicationFiled: June 22, 2020Publication date: November 24, 2022Inventors: Elias Quijano, Stanley Oyaghire, W. Mark Saltzman, Peter Glazer
-
Publication number: 20220339294Abstract: Compositions containing populations of nanoparticles that show selective uptake by tissues and other cell types such as lung cells and/or bone marrow cells are described. The nanoparticles show this uptake by virtue of their size and in the absence of a targeting agent on the surface of the nanoparticles, i.e., passive targeting. The population of nanoparticles contain poly(lactic acid-co-glycolic acid), have a diameter between about 70 nm and about 220 nm, and at least 90% of the nanoparticles have a diameter between about 110 nm and about 129 nm. The nanoparticles are manufactured using a microfluidic system. The compositions can be used to treat lung- and/or blood-related genetic disorders in in vivo gene editing technologies.Type: ApplicationFiled: September 9, 2020Publication date: October 27, 2022Inventors: Hanna Mandl, Elias Quijano, W. Mark Saltzman, Peter Glazer
-
Publication number: 20220280656Abstract: Peptide nucleic acid (PNA) oligomers that target the ?-globin gene and can increase the frequency of recombination of donor oligonucleotide at the site of a Sickle Cell Disease mutation are provided. Nanoparticle formulations for delivering the PNA oligomers and donor oligonucleotides, and potentiating agents for increase the frequency of recombination of the donor oligonucleotide are also provided. Methods of using the PNA oligomers, donor oligonucleotides, nanoparticles, and potentiating agents for treating Sickle Cell Disease are also provided.Type: ApplicationFiled: July 31, 2020Publication date: September 8, 2022Inventors: Peter Glazer, Elias Quijano, W. Mark Saltzman, Hee Won Suh
-
Publication number: 20210338815Abstract: Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.Type: ApplicationFiled: August 30, 2019Publication date: November 4, 2021Inventors: Elias Quijano, Adele Ricciardi, Raman Bahal, Audrey Turchick, Nicholas Economos, W. Mark Saltzman, Peter Glazer
-
Publication number: 20210340280Abstract: Compositions for enhanced gene editing and methods of use thereof are. The composition contains a cell-penetrating antibody and a donor oligonucleotide containing a sequence that can correct a mutation in a cell's genome. Preferably, the composition does not contain a nuclease, PNA, or nanoparticle. The compositions are used to modify the genome of a cell by contacting the cell with an effective amount of the composition. Genomic modification occurs at a higher frequency both ex vivo and in vivo, when cells are contacted with the cell-penetrating antibody and donor oligonucleotide as compared to the absence of the cell-penetrating antibody.Type: ApplicationFiled: August 30, 2019Publication date: November 4, 2021Inventors: Elias Quijano, Audrey Turchick, Peter Glazer
-
Patent number: 11136597Abstract: Compositions and methods for enhancing targeted gene editing and methods of use thereof are disclosed. In the most preferred embodiments, gene editing is carried out utilizing a gene editing composition such as triplex-forming oligonucleotides, CRISPR, zinc finger nucleases, TALENS, or others, in combination with a gene modification potentiating agent such as stem cell factor (SCF), a CHK1 or ATR inhibitor, or a combination thereof. A particular preferred gene editing composition is triplex-forming peptide nucleic acids (PNAs) substituted at the ? position for increased DNA binding affinity. Nanoparticle compositions for intracellular delivery of the gene editing composition are also provided and particular advantageous for use with in vivo applications.Type: GrantFiled: February 16, 2017Date of Patent: October 5, 2021Assignees: Yale University, Carnegie Mellon UniversityInventors: W. Mark Saltzman, Peter Glazer, Raman Bahal, Nicole Ali McNeer, Danith H. Ly, Elias Quijano
-
Publication number: 20200054553Abstract: Biodegradable contraceptive implants and methods of making and using thereof, are preferably formed of poly(?-pentadecalactone-co-p-dioxanone) [poly(PDL-co-DO)], a family of polyester copolymers that degrade slowly in the presence of water. The material is suitable as the basis of a biodegradable contraceptive implant that provides sustained release of a progestin at a rate similar to a commercially available nondegradable implant. In a preferred embodiment, the progestin is levonorgestrel (LNG), a hormone that prevents pregnancy by preventing the release of an egg from the ovary or by preventing fertilization of the egg by sperm. The implant may be inserted subcutaneously, allowing degradation over a period of up to about 18 or 24 months, eliminating the need for removal by a trained practitioner.Type: ApplicationFiled: October 24, 2017Publication date: February 20, 2020Inventors: W. Mark Saltzman, Elias Quijano, Fan Yang, Zhaozhong Jiang, Derek Owen
-
Publication number: 20170283830Abstract: Compositions and methods for enhancing targeted gene editing and methods of use thereof are disclosed. In the most preferred embodiments, gene editing is carried out utilizing a gene editing composition such as triplex-forming oligonucleotides, CRISPR, zinc finger nucleases, TALENS, or others, in combination with a gene modification potentiating agent such as stem cell factor (SCF), a CHK1 or ATR inhibitor, or a combination thereof. A particular preferred gene editing composition is triplex-forming peptide nucleic acids (PNAs) substituted at the ? position for increased DNA binding affinity. Nanoparticle compositions for intracellular delivery of the gene editing composition are also provided and particular advantageous for use with in vivo applications.Type: ApplicationFiled: February 16, 2017Publication date: October 5, 2017Inventors: W. Mark Saltzman, Peter Glazer, Raman Bahal, Nicole Ali McNeer, Danith H. Ly, Elias Quijano